Abstract:Patients with pancreatic ductal adenocarcinoma (PDAC) have a poor prognosis due to late presentation of disease and frequent resistance to therapy. Immunotherapy regimens have uniformly failed in PDAC, which has long been considered an immunologically cold tumor. It is believed that immunotherapy has been unsuccessful in PDAC due to its dense, fibrotic, and immunosuppressive microenvironment. Cancer-associated fibrosis may account for up to 90% of the PDAC microenvironment, thus further study of this immunosuppressive component is urgently needed. Methods Human PDAC surgical specimens were procured, sectioned, and allocated for histology, flow cytometry, tumor-infiltrating lymphocyte (TIL) expansion, and fibroblast culture. For histology, tumor slices were saved in 10% formalin and wax embedded. Histological PDAC slides were stained against fibroblasts markers alpha smooth muscle actin, fibroblast activation protein; and T-cell markers CD3, CD69, CD25, FOXP3. First, tumor sections were digested using mechanical and chemical techniques. For flow cytometry, digested tumor cells were stained with fluorescent conjugated antibodies targeting CD45, CD3, CD4, CD8, CD25, CD69, PD-1 and ICAM. For TIL isolation and expansion, resultant single-cells were bead-isolated for CD3 positive cells, cultured and expanded with 2000 IU interleukin-2 and 1.5 mg/mL anti-CD3/CD28 antibodies. For fibroblast culture, fibroblasts were bead isolated and sub-cultured in RPMI supplemented with FGF. TILs were co-cultured with patient-derived fibroblasts/fibroblast media with the PD-L1 inhibitor Atezolizumab. TILs were then analyzed by flowcytometry, and media from co-culture was analyzed via ELISA for gamma interferon release. Results TILs isolated from PDAC (N=5) co-cultured with patient-matched fibroblasts or media were phenotypically compared using flow cytometry and measure for gamma interferon release. Interestingly, TILs co-cultured with fibroblasts or fibroblast media showed improved expansion over peripheral blood derived control T-cells, but both groups showed highly impaired gamma interferon release. Co-cultured TILs had high levels of PD-1 and low levels of CD69, compared to control TILs, indicating a suppressed phenotype. TILs co-cultured with fibroblasts and Atezolizumab resulted in significantly increased CD69 expression and gamma interferon release (P>0.05), indicating an activated phenotype. Histological PDAC slides showed abundant T-cell infiltrates with minimal CD69 expression. CD25+ T-cells were identified throughout fibrotic areas of the TME. Conclusion Here, we challenge the long-held belief that PDAC is immunologically cold as our tumor cross-sections (N=5) were rich in T-cells. More importantly, our results show that tumor-derived fibroblasts appear to play a role in suppression of TIL function, which is partially reversible with immunomodulatory techniques (e.g., anti-PDL1therapy). Our results warrant further investigation into targeting CAFs in PDAC microenvironment to improve patient response to immunotherapy. Citation Format: Charles Bailey, Hannah Mcdonald, Anna Reagan, Michael Cavnar, Mautin Barry-Hundeyin, Prakash Pandalai, Joseph Kim. Pancreatic ductal adenocarcinoma derived cancer-associated fibroblasts suppress tumor infiltrating lymphocytes in the tumor microenvironment [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research; 2024 Sep 15-18; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2024;84(17 Suppl_2) nr A056.

Abstract 6533: Pivotal role of specific LYVE1+ tissue resident macrophages in PDAC progression & immunotherapy resistance

Abstract 653: Tumor cell-macrophage crosstalk drives immune suppression in pancreatic cancer

Abstract 5373: Decoding the role of intrinsic pancreatic cellular signaling in shaping the immunosuppressive tumor microenvironment

Macrophage proliferation machinery leads to PDAC progression, but susceptibility to innate immunotherapy

Abstract 3988: Deep spatial immunophenotyping of lymphoid aggregates in pancreatic cancer using multi-omic integration of ultra high-plex proteomics and transcriptomics

Abstract B020: Charting the cellular heterogeneity of primary and metastatic PDAC microenvironment

Abstract PR021: CCR1 expression defines pancreatic tumor associated macrophages and drives their immunosuppressive properties

CTHRC1+ fibroblasts and SPP1+ macrophages synergistically contribute to pro-tumorigenic tumor microenvironment in pancreatic ductal adenocarcinoma

Abstract 1596: Disrupting local immunosuppression by combined myCAF/myeloid targeting in pancreatic cancer

Abstract 1165: Mechanisms of therapeutic resistance in pancreatic cancer identified by single-cell spatial transcriptomics and genetically-engineered stromal tumoroids

Combining bulk and scRNA-seq to explore the molecular mechanisms governing the distinct efferocytosis activities of a macrophage subpopulation in PDAC

Abstract 4589: Deciphering collagen-responsive mechanism in pancreatic tumor progression and immunology at single-cell resolution

Abstract 1948: Resistance to RAS inhibition promotes remodeling of the immunosuppressive microenvironment of pancreatic cancer

Abstract C020: Unconvering the hidden immunosuppressive landscape in pancreatic ductal adenocarcinoma

Abstract 1384: Highly metastatic PDAC adopts mesenchymal morphology and spatially coordinates endothelial cells with macrophages

Abstract 2691: Mapping the landscape of innate immune pattern recognition receptors in pancreatic cancer

Abstract A056: Pancreatic ductal adenocarcinoma derived cancer-associated fibroblasts suppress tumor infiltrating lymphocytes in the tumor microenvironment

Abstract A033: Blocking TNF-a producing macrophage activates antitumor immunity in pancreatic cancer via IL33

Abstract 1589: Integrated multiomics analysis revealed the significance of Transgelin in driving pancreatic cancer-associated fibroblast-mediated cancer progression

Abstract B019: Tumor-derived PTHrP molds an immunosuppressive microenvironment

Abstract PO4-25-05: LYVE-1 expressing macrophages modulate the extracellular matrix and contribute to mammary tumor growth